RADLogics Inc. Company Profile

Background

Overview

Founded in 2010, RADLogics Inc. is a healthcare software company specializing in AI-powered solutions for medical image analysis. With headquarters in New York, NY, and Tel Aviv, Israel, the company aims to enhance radiologists' accuracy and productivity, thereby improving patient outcomes. As a pioneer in applying artificial intelligence and machine learning to medical imaging, RADLogics focuses on reducing diagnostic turnaround times by automating detection and report generation functions.

Mission Statement

RADLogics is dedicated to harnessing the power of AI to provide machine learning image analysis solutions that improve radiologists’ accuracy and productivity while enhancing patient outcomes.

Key Strategic Focus

Core Objectives

• Enhancing Radiology Efficiency: Develop AI-driven tools to support image analysis, aiming to improve radiologists' productivity and diagnostic accuracy.

• Improving Patient Outcomes: Utilize advanced analytics to facilitate faster and more accurate diagnoses, leading to better patient care.

Areas of Specialization

• AI-Powered Image Analysis: Specializes in developing algorithms for the automatic detection and quantification of abnormalities in medical imaging modalities such as CT scans and X-rays.

• Workflow Integration: Focuses on seamless integration of AI solutions into existing radiology workflows to ensure minimal disruption and maximum efficiency.

Key Technologies Utilized

• Machine Learning Algorithms: Employs advanced machine learning techniques to analyze imaging data, enabling rapid and accurate detection of medical conditions.

• Big Data Analytics: Utilizes big data analytics to process and interpret large volumes of imaging data, facilitating comprehensive analysis and reporting.

Primary Markets Targeted

• Healthcare Institutions: Targets hospitals and clinics seeking to enhance their radiology departments with AI-powered diagnostic tools.

• Radiology Practices: Aims to support independent radiology practices in improving diagnostic accuracy and efficiency.

Financials and Funding

Funding History

• Angel Investment (2011): Raised $850,000 in initial funding.

• Series A (2014): Secured $1.5 million to support early-stage development and operations.

• Later Stage VC (2019): Obtained additional funding to further product development and market expansion.

Notable Investors

• REDDS Capital: Participated in funding rounds, supporting the company's growth initiatives.

• Individual Investors: Including Bob Schindler, Igal Ladabaum, and Oded Tamir, who have contributed to the company's financial backing.

Utilization of Capital

The funds raised have been allocated towards:

• Product Development: Advancing AI algorithms and enhancing the medical image analysis platform.

• Market Expansion: Extending the company's reach into new geographic markets and healthcare sectors.

• Operational Growth: Scaling operations to support increased demand and deployment of solutions.

Pipeline Development

Key Products and Solutions

• AI-Powered Medical Image Analysis Platform: Offers automated detection, measurement, and reporting of abnormalities in CT and X-ray images.

• COVID-19 Detection Algorithms: Developed AI solutions to detect lung abnormalities compatible with COVID-19, aiding in rapid diagnosis and patient management.

Development Stages

• FDA Clearance: The company's AI applications have received FDA clearance, facilitating deployment in clinical settings.

• Global Deployment: Solutions have been deployed globally, processing millions of scans from clinical sites in the U.S., Europe, Russia, China, and India.

Target Conditions

• Pulmonary Diseases: Focuses on detecting conditions such as lung cancer and COVID-19-related abnormalities.

• Other Pathologies: Aims to expand detection capabilities to a broader range of medical conditions through ongoing research and development.

Anticipated Milestones

• Expansion of AI Algorithms: Continued development of new algorithms to cover additional medical imaging modalities and conditions.

• Regulatory Approvals: Pursuing further regulatory clearances to facilitate broader adoption of solutions.

Technological Platform and Innovation

Proprietary Technologies

• Patented AI Medical Image Analysis Platform: Enables rapid development and deployment of AI algorithms, integrating seamlessly into existing radiology workflows.

Significant Scientific Methods

• Deep Learning Algorithms: Utilizes deep learning techniques to enhance the accuracy and efficiency of image analysis.

• Advanced Big Data Analytics: Applies sophisticated analytics to interpret complex imaging data, supporting comprehensive diagnostic assessments.

Leadership Team

Executive Profiles

• Moshe Becker, CEO & Co-Founder: With over 25 years of experience in senior management and engineering positions in the IT industry, Moshe has built a culture of innovation at RADLogics. He holds an Executive MBA from Claremont Graduate University and a BS in Electrical Engineering from Tel Aviv University.

• Hayit Greenspan, PhD, Chief Scientist & Co-Founder: A Professor of Biomedical Engineering at Tel Aviv University, Hayit has published over 200 leading international journals and conferences. She received her Ph.D. in Electrical Engineering from the California Institute of Technology.

• Patrick D. Browning, MD, MA, MSL, Global Chief Medical Officer: Patrick has a background in diagnostic radiology and has held leadership roles in medical imaging divisions. He earned his medical degree from UC Davis and completed a body-imaging fellowship at Stanford University Medical Center.

• Linda McManus, Executive Vice President and General Manager, US, Canada, Americas: With over 25 years of healthcare technology experience, including senior roles at Nuance, Linda leads RADLogics' efforts to scale the medical imaging AI platform in the Americas.

• Alexander Chikulaev, General Manager for Russia